BPC-157 TB-500 brings together unapproved ingredients intended for repair.
This page answers questions about the names, healing claims, and possible harms. The ingredients were mostly studied separately. You can see why animal results still leave your treatment and safety unanswered.
The ingredient names don't establish an approved healing treatment
Wolverine is a mixture proposed to help injuries mend. These answers explain the names and the findings behind healing claims. You can also see which questions still lack tests in people.
Wolverine means BPC-157 with TB-500, without a new drug approval
A “stack” means substances used together [1]. This pair has no approval as medical treatment. Researchers identify the ingredients separately. Calling the combination Wolverine gives you neither an approved medicine nor proof that treatment works [1].
BPC-157 and TB-500 started with different body substances
BPC-157 was designed using a stomach-fluid protein, a substance working inside the body. Lab tests found better cell survival and new blood vessels [1]. TB-500 was made by copying only part of Thymosin Beta-4. The copy holds a protein involved in a cell's movement and changing shape [5]. That lab result explains what happened within cells, but your own injury remains untested unless a study gives the actual substance to injured people and checks how their healing changes.
BPC-157 and TB-500 differ in size as well as design
BPC-157 is larger than the small TB-500 copy [5]. The substances have different designs and different cell effects. TB-500 copies only a short part of the body's Thymosin Beta-4 [4]. A test giving the whole substance cannot prove that the copy helps you. The ingredient given in a study matters.
BPC-157 and TB-500 healing claims rest mainly on animal work
The scientists tested BPC-157 after muscle, skin, tendon, and ligament injuries [1]. A tendon connects bone with muscle; a ligament holds a joint together. Other claims come from Thymosin Beta-4 tests examining wounds and cell movement [4]. Animal repair doesn't establish the same healing in people. Treatment with the mixture has no approval [13].
BPC-157 and TB-500 were combined in hope, without proof of a gain
BPC-157 helped cells survive and encouraged new vessels [2]. TB-500 held onto a protein helping movement within cells [3]. Researchers proposed that both effects might aid repair together. No treatment comparison established that added benefit for you [1].
Better animal healing still leaves the mixture's human benefit unknown
BPC-157 + TB-500 has no human comparison showing improved healing
No trial compared BPC-157 + TB-500 with other human care. Animal results haven't established a mixture or amount that adds repair benefit [1]. The small BPC-157 human studies didn't give both together [8]. You still lack a healing result for the mixture.
BPC-157 reviewers left TB-500's contribution unproved
No treatment trial proved an extra gain from combining the ingredients [1]. A 2025 BPC-157 review examined neither TB-500 nor combined use [6]. Separate lab effects supplied the reason for proposing both. The review doesn't tell you that both repair an injury better.
BPC-157 and TB-500 papers haven't filled the gaps in people
The 2024–2026 papers include a 2025 BPC-157 review counting 36 studies. Only 1 involved people; published findings didn't establish human safety [6]. A 2026 Sports Medicine review examined proposed care for muscle, joint, and bone injuries [7]. A 2025 review called for further BPC-157 tests [8]. Work from 2024–2025 also added animal findings [9].
BPC-157 + TB-500 reviewers still need better tests of harm
BPC-157 animal repair looked hopeful, but reviewers judged the overall proof weak. Published results left human safety unsettled [6]. Another review warned that unapproved treatments could cause serious harm. Few sound human safety tests were available [7]. No fair comparison gave the mixture to check healing [1].
BPC-157 and TB-500 cell results can't answer your treatment question
After BPC-157, extra vessels grew and growth hormone affected tendon cells more strongly [2]. That hormone is a body chemical helping growth and repair. TB-500 held a protein helping movement inside cells [3]. The scientists proposed combining those different repair effects [2]. They didn't prove better healing for your tendon from both.
TB-500 needs its own healing tests, separate from Thymosin Beta-4
The small TB-500 copy held actin, the protein helping movement inside a cell. The 1:1 finding meant one copy held one actin protein [3]. Actin helps cells reach wounds and grow back over damage. Most repair credited to TB-500 followed treatment with whole Thymosin Beta-4 [4]. The smaller copy's benefit needs its own test.
BPC-157 and TB-500 blood-vessel claims concern separate experiments
BPC-157 affected growing vessels in animals. Dish tests examined human cells separately [2]. The people supplying cells didn't receive the treatment. Other vessel tests used Thymosin Beta-4 and found that cells lining blood vessels moved more readily [4]. Those separate results don't prove improved blood flow from the mixture in you.
Bottle labels and animal times don't give you a treatment plan
BPC-157 and TB-500 haven't had their stay measured in people
No established time tells how long the mixture or either separate ingredient remains in people [1]. The amount of unchanged BPC-157 fell by half in rats and dogs in less than 30 minutes. That fall includes drug broken down or removed from the body. No such time is established for the short TB-500 copy [1]. Your shot times cannot be set from animal breakdown.
A 10mg BPC-157 / TB-500 label cannot rule out unwanted material
Research laboratories dissolve dried powder with prepared water, then refrigerate the mixture [1]. The water keeps germs out or stops germs growing. Milligrams are thousandths of a gram; the label's weight doesn't prove the contents. Those steps leave both the amounts and unwanted substances unchecked. Germ control doesn't answer either question for you.
BPC-157 and TB-500 have no trial supporting a large first amount
No trial supports a large first amount followed by smaller amounts [6]. Animal experiments differed in both amounts and timing. No published test found a proper amount for the mixture [4]. Their shot schedules cannot become a safe plan for your care.
No human mixture test has settled the cancer concerns
BPC-157 and TB-500 lack the tests needed to settle human safety
One review found three small human BPC-157 studies. Another found only one because reviewers selected different papers. Neither established safety. The small TB-500 copy lacks a completed human treatment comparison [8]. Thymosin Beta-4 research linked the larger substance with tumors and vessels feeding them [4]. No test measured those harms in people given both ingredients.
TB-500's cancer question comes from whole Thymosin Beta-4 research
The scientists found more of the larger substance in several cancers. Lab work linked the larger substance with tumor blood vessels and cancer spread [4]. Those repair effects could help tumors too. No human test proved a cancer caused by using the mixture. Nobody ruled that risk out through a human test either [6]. Your cancer-risk question remains unanswered.
The pharmacy notices don't establish permission to supply the mixture
BPC-157 and TB-500 lack approval and are banned for athletes
FDA has approved none of the mixture's ingredients for medical use, separately or together [13]. The World Anti-Doping Agency writes the drug rules governing regulated sport. The agency bars BPC-157 because the substance lacks approval. TB-500 and whole Thymosin Beta-4 are also barred under growth-related rules [7]. Pharmacy discussions don't settle these separate bans.
Wolverine pharmacy requests were withdrawn without a safety clearance
The applicants asked FDA to consider the ingredients for pharmacy-made medicine. Those applicants later stopped pursuing their requests. FDA's notice dated September 29, 2023 assigned both to Category 2 [13][14]. FDA's Category 2 marks serious safety risks. On its page current as of April 22, 2026, FDA lists withdrawn requests. Withdrawal isn't approval. The warnings remain. What withdrawal permits a pharmacy to supply hasn't been explained by FDA [13][14]. Sports bans also cover the ingredients [7]. The Wolverine legal status and FDA 503A pharmacy rules page explains the medicine rules. Under that law, medicine is mixed to fill a particular patient's prescription. Your permission question cannot be settled by withdrawal of the requests.
BPC-157 withdrawal leaves the pharmacy supply question open
The FDA page dated April 22, 2026 lists the BPC-157 request as withdrawn. Category 2 doesn't include that ingredient on this page. The papers don't establish permission for a 503A pharmacy after withdrawal [13]. Under 503A/503B rules, examination, prescription, and ingredient requirements still apply [14]. Holding a prescription doesn't resolve your supply question.
FDA 503A advisers' meeting didn't grant Wolverine treatment approval
The September 29, 2023 notice put both ingredients into FDA's 503A Category 2. Withdrawn requests are recorded on the page dated April 22, 2026 [13]. Advisers considered the ingredients for the 503A list at their July 23–24, 2026 meeting. Discussion couldn't add them to the list. The advisers' votes weren't published [15]. That meeting supplies no approval for your treatment.